Zovighian Bernard J's Form 4 filing
Edwards Lifesciences Corp (EW) · filed May 7, 2024
- Accession no.
- 0001225208-24-005743
- Filed
- May 7, 2024
- Trade date
- May 3-6, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market purchases total $49.8K. It was filed 4 days after the trade.
This filing was later replaced by the amendment 0000950170-24-073281 (Jun 13, 2024). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Zovighian Bernard JCIK 0001665141 | Director, Officer (CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 3, 2024 | Common Stock | FTax withholdingDisposed | −527 | $85.06 | −$44,826.62 | 44,288.9 | Direct | |
| May 4, 2024 | Common Stock | MOption exerciseAcquired | +6,265 | $0.00F1 | $0 | 50,553.9 | Direct | |
| May 4, 2024 | Common Stock | FTax withholdingDisposed | −3,718 | $85.25 | −$316,959.5 | 46,835.9 | Direct | |
| May 6, 2024 | Common Stock | PPurchaseAcquired | +580.26 | $85.74 | +$49,751.49 | 3,267.66 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 4, 2024 | Common Stock | MOption exerciseDisposed | −6,265 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.
Referenced by the price of 1 transaction in Table I.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.